Medicines and poisons

Medicines and poisons

Medicines and Poisons is responsible for the monitoring and control of supply of scheduled substances in the Northern Territory (NT).

The following areas come under Medicines and Poisons and can be found on these pages or on the NT Government website:


Medicines and poisons enforces compliance of these Acts:


The Medicines and Poisons program has these key responsibilities:

  • issuing licences, registrations and authorisations under the relevant Acts
  • inspecting premises for compliance storage, record keeping, packaging, labelling, advertising and supply
  • scheduling of poisons and medicines
  • monitoring the movement of S8 medicines
  • issuing authorisations for the NT Opiate Pharmacotherapy Program
  • secretariat support for the Department of Health statutory committees:  


Medicines and Poisons
5th floor Manunda Place
38 Cavenagh Street
Darwin NT 0800

Phone: (08) 8922 7341
Fax: (08) 8922 7200


PO Box 40596
Casuarina NT 0811

Medicines and poisons notices

  • This page contains Government Gazette notices relating to the Medicines, Poisons and Therapeutic Goods Act 2012.
  • For COVID-19 vaccination administration protocols, go to the COVID-19 Vaccine Protocols page.

The Government Gazette notices allow certain health practitioners to possess, administer and supply scheduled substances under protocol.

Organisations outside NT Health need to use one of these application forms to apply for a new approval or request an update to an existing approval. The completed form and all attachments must be emailed to

Applications approved by the Chief Health Officer will be published in the NT Government Gazette before they take effect.


Sponsoring Area

Health Practitioner


G34 2021 p8-11Oral Health ServicesDental Therapist, Dental Hygienist or Oral Health Therapist 25 August 2021
G29 2021 p2-4Royal Flying Doctor ServiceNurses and Midwives 21 July 2021
G23 2021 p6-9 Darwin Occupational Services (DOS) Nurses 9 June 2021
S12 2021 Medimobile Nurses 6 May 2021
G18 2021 - p1-4 Urban Schools Nurses and Midwives 5 May 2021
S11 2021 HCA Corporate Health Nurses 20 April 2021
G13 2021 p2-3 Chief Health Officer Medicines and Poisons Officers 31 March 2021
G13 2021 p4-7 Public Hospital Maternity Midwives 31 March 2021
G11 2021 p1-4Urban Community Health ClinicsNurses, Midwives and ATSIHPs 17 March 2021
S2 2021 Chief Health Officer Covid-19 response – declared site Darwin   15 January 2021
G1 2021 p5-14 Centre for Disease Control – Meningococcal B Vaccine Study  “B Part of it NT” Nurses, Midwives and ATSIHPs 6 January 2021
G39 2020 p4 Chief Health Officer Covid-19 response – declared sites Alice Springs and Tennant Creek   30 September 2020
G37 2020 p3-10 Non-government community health centres and clinics Nurses and Midwives and ATSIHPs 16 September 2020
G37 2020 p11-18 NT Government primary health care centres Nurses and Midwives and ATSIHPs 16 September 2020
G26 2020 p10-11 RDH ENT outpatient - declarations and approval Nurse and Midwives 1 July 2020
G20 2020 p4-7 Renal Services Nurses and ATSIHPs 20 May 2020
S30 2020 Immunisation - Qualifications Pharmacists 12 May 2020
G16 2020 Howard Springs facility declared place   22 April 2020
G13 2020 SMG Health Nurses 1 April 2020
G21 2019 Immunisation - prescribed qualifications to supply, administer or possess vaccines Aboriginal and Torres Strait Islanders Health Practitioners 22 May 2019
S22 2019 CareFlight Nurses, Midwives and Paramedics 12 April 2019
S108 2018 AusHealth Corporate Pty Ltd Nurse and Midwives 19 December 2018
S81 2018 Northern Territory Alcohol and Drug Services Nurse and Midwives 5 October 2018
S55 2018 Correctional facilities centres and clinics Nurses and Midwives and ATSIHPs 18 July 2018
S81 2017 Centre for Disease Control (CDC) - Immunisation Nurses and Midwives and ATSIHPs 10 Nov 2017
S56 2017 Sexual Assault Referral Centres Nurses 2 August 2017
S25 2017  Immunisation - prescribed qualifications to supply, administer or possess vaccines Nurses, Midwives and ATSIHPs 16 May 2017
S94 2016 Sonic Healthplus Darwin Nurses 17 Aug 2016
S28 2016 NT Renal Services Nurses and Midwives 14 April 2016
S22 2016 VaxWorks Health Services Pty Ltd Nurses and Midwives 7 April 2016

S43 2015

Alice Springs Hospital Emergency Department Nurses and Midwives 6 May 2015
S36 2015 p4-5 Infection Prevention and Management Units Nurses and Midwives 23 Apr 2015
S35 2015 p9-10 Immunisation - Approval of SSTP for NCCTRC Pharmacists 21 Apr 2015

S24 2015

Primary Health Care, DoH - Police Stations and Watchhouses Nurses and Midwives 17 Mar 2015

G25 2014

Centre for Disease Control (CDC) - Extra vaccines and medicines ATSIHPs 25 Jun 2014
G25 2014 Centre for Disease Control (CDC) - Extra vaccines and medicines Nurses and Midwives 25 Jun 2014

S31 2014

Home Birth Services Midwives 30 Mav 2014

S24 2014

Family Planning Welfare NT (FPWNT)

Nurses and Midwives

1 May 2014

The following Government Gazettes mark the commencement of Medicines, Poisons and Therapeutic Goods Act 2012, in 2014.




G17 2014

Assent to Proposed Laws Medicines, Poisons and Therapeutic Goods Amendment Act (No 12 of 2014) 30 Apr 2014

G16 2014

Declared Medical Conditions 23 Apr 2014

G16 2014

Approval for Pharmacist to Supply S8 Substances on Interstate Prescription (Cross-Border Communities) 23 Apr 2014
G15 2014 Notification of Subordinate Legislation - Medicines, Poisons and Therapeutic Goods Regulations 16 Apr 2014

S8 Code of Practice and related documents



G10 2020 p2

Notice of making S8 Code of Practice – new edition of Part 4 Opioid Substitution Treatment

11 March 2020
G10 2020 p3 Declaration of Restricted S8 Substances 11 March 2020
G26 2020 p12-14

Exemption - S8 Authorisation for hospital patients

1 July 2020
G26 2020 p15-16

Exemption - S8 Authorisation - Authorised Health Practitioners at AODS and Corrections

1 July 2020
G26 2020 p17-18

Exemption - S8 Authorisation - Methadone liquid for patients in intensive care

1 July 2020
G26 2020 p19-20 Exemption - S8 Authorisation - Methadone liquid for palliative care patients 1 July 2020
G26 2020 p21-23 Exemption - S8 Authorisation - Patient transfers to and from AODS and corrections 1 July 2020
G26 2020 p24-27 Exemption - S8 Authorisation - Shared care providers - Patient transfers to and from AODS and corrections 1 July 2020

Medical practitioners and schedule 8 medicines

This page has information for medical practitioners about the prescription and supply of Schedule 8 (S8) substances.

The Medicines, Poisons and Therapeutic Goods Act 2012 states that the following applies to medical practitioners:

  • authorised prescribers, including doctors, nurse practitioners, eligible midwives, dentists and veterinarians, are prohibited from prescribing a S8 substance to themselves
  • pharmacists are only allowed to dispense S8 substances if the prescriber is practising in the Northern Territory (NT), as evidenced by the practice address on the prescription
  • the Chief Health Officer (CHO) can also declare Schedule 4 substances to be restricted if they are being used in a harmful manner.

For information on the Schedule 8 contract list please contact Medicines and Poisons during office hours on (08) 89227 341 or by emailing

Read about the laws that apply to S8 drugs in the S8 Code of Practice, further down this page.

Restricted S8 substances

S8 substances are classified as either restricted or unrestricted.

Restricted S8 substances include:

  • buprenorphine depot Injections (Buvidal® and Sublocade®)
  • buprenorphine (Subutex) 0.4mg, 2mg and 8mg for sublingual administration
  • buprenorphine/naloxone (Suboxone) 2mg/0.5mg, 8mg/2mg in film form for sublingual or buccal administration
  • methadone liquid 5mg/mL for oral administration
  • dexamfetamine
  • lisdexamfetamine
  • methylphenidate.


The following applies for the supply of dexamphetamine, lisdexamfetamine and methylphenidate:

  • authorisation from the CHO is required for each individual patient before a prescription can be written
  • only paediatricians, psychiatrists, physicians, neurologists and registrars in training in these disciplines may make the decision to initiate supply
  • other medical practitioners may continue supply after one of the above specialists or registrars has done so
  • under such a co-management situation the patient must be seen by a specialist or registrar at least every two years
  • paediatricians may initiate supply without an authorisation, but must obtain an authorisation if supply exceeds 30 days.

The following applies for the supply of buprenorphine (Subutex), buprenorphine/naloxone (Suboxone), buprenorphine depot Injections (Buvidal® and Sublocade®) and methadone liquid:

  • medical practitioners providing pharmacotherapies for opioid dependence need to complete approved training initially and demonstrate continued clinical involvement and the undertaking of refresher training
  • an authority from the CHO to supply buprenorphine, buprenorphine/naloxone, buprenorphine depot injections and methadone is required for each individual patient before a prescription can be written or supplied
  • the framework for supply of these medications covers the writing of prescriptions, details of authorisation requirements, period of supply, dispensing of medications and takeaway privileges.

Unrestricted S8 substances

Unrestricted S8 substances include morphine and oxycodone.


The following applies for the supply of unrestricted substances:

  • medical practitioners may supply unrestricted S8 substances for the treatment of medical and surgical conditions but not for the treatment of addiction
  • a medical practitioner may only supply unrestricted S8 substances for up to 15 patients at a time
  • this number does not include palliative care patients, hospital inpatients or those in need of emergency treatment
  • a medical practitioner may apply to the CHO for an authority to prescribe unrestricted S8 substances for more than this number of patients
  • medical practitioners must notify the CHO of the supply of unrestricted S8 substances under certain circumstances, for example if supply exceeds 8 weeks, if certain dosage levels are exceeded or if their circumstances may be conducive to possible abuse.

Over-the-counter codeine product advice

Over-the-counter codeine containing medicines will be prescription only nationally from 1 February 2018.

Information for consumers, health practitioners, wholesalers and product sponsors is available on the Therapeutic Goods Administration (TGA) Codeine Hub.

An advice sheet for Northern Territory GPs is available to assist patients who present with codeine related issues.

Electronic Prescribing

Electronic prescriptions may be issued in accordance with the Electronic Transactions (Northern Territory) Act 2000.

24-hour clinical advice

The Drug and Alcohol Clinical Advisory Service (DACAS) offers professional advice to medical practitioners, pharmacists and other health professionals 24-hours.

Call DACAS on 1800 111 092.

Storage and transport

Health professionals producing or storing controlled Schedule 8 drugs read the Code of Practice for Schedule 8 Substances: Storage and Transport.

Schedule 8 code of practice

Document title


Document Description

Code of Practice S8s - Volume 1

Code of Practice S8 Substances


Code of Practice S8s - Volume 1 - Part 4

Code of Practice S8 Substances


Code of Practice S8s - Volume 1 - Part 4B

Code of Practice S8 Substances

Code of Practice S8s - Volume 2

Code of Practice S8 Substances


Appendix A - Notification of Supply of an Unrestricted S8 Substance

Appendix A

Notification Form

Appendix B - Application for Authority to Prescribe a Restricted S8 Psychostimulant Medication

Appendix B

Application Form

Appendix C - Application for Authority to Prescribe a Restricted S8 Substance for Addiction

Appendix C

Application Form

Appendix D - Clinical Assessment for the Level of Supervised Dosing

Appendix D

Assessment Tool

Appendix E1 - Application for Variation to Regular OSD Takeaway USD - Buprenorphine, Naloxone

Appendix E1

Application Form

Appendix E2 - Application for Variation to Regular OSD Takeaway USD - Methadone, Buprenorphine 

Appendix E2

Application Form

Appendix F - Applications for OSD Takeaway USD for Travel

Appendix F


Agreement for patients prescribed general medications
Opiate Pharmacotherapy Contract
Drug Loss Discrepancy Report Form
Information sheets
Requirements of Prescriptions for S8 Substances
Information for Patients on S8 Medications 
Interstate S8 prescriptions state phone and fax:
Phone: (02) 6205 0998
Fax: (02) 6205 0997
Main switch phone: (02) 9391 9944
Fax: (02) 9424 5860
Non-methadone phone: (02) 9424 5923
Fax: (02) 9424 5889
Methadone phone: (02) 9424 5921
Fax:(02) 9424 5885
Phone: (07) 3328 9890
Fax: (07) 3328 9821
South Australia
Phone: 1300 652 584
Fax: 1300 658 447
Phone: (03) 6166 0400
Fax: (03) 6233 3904
Phone: 1300 364 545 select #1
Fax: 1300 360 830
Western Australia 
Phone: (08) 9222 6883
Fax: (08) 9222 2463
Phone: (08) 8922 7341
Fax: (08) 8922 7200
Medical Practitioner Guide to Supplying Isotretinoin (47KB)
The Scheduled Substances Clinical Advisory Committee (48KB)
Patient Delivered Partner Therapy (47KB)
Interstate Health Departments - S8 Drug Monitoring (44KB)
Recommended reading on treatment of pain
Opioid recommendations in general practice on the NSW Health website.
National Prescribing Service (NPS) Medicine Wise website
Patient guide to managing pain and opioid medicines Choosing Wisely Australia website

Related information

Read more about scheduled substances in the Clinical Advisory Committee (CLAC).

For information on the following topics go to medicines and poisons safety:

  • therapeutic goods recalls
  • buying medicines online.

NTScript information for health professionals

Prescription medicines are an important tool to manage the health of Territorians, however there is growing evidence nationally that particular medicines carry a high risk of dependence, misuse and over-use that is leading to increasing numbers of avoidable hospitalisations and death.

In 2018 State and Territory Health Ministers in conjunction with the Commonwealth Department of Health agreed to participate in a federated Real Time Prescription Monitoring solution based on the Victorian SafeScript model. Under this model all the states and territories will integrate with a national data exchange to enable real time prescription monitoring across the jurisdictions.

Prescription monitoring in the NT

The NT Chief Health Officer has undertaken monitoring of Schedule 8 (S8) Controlled Drugs since 1983, with pharmacies providing a weekly report of dispensed S8 prescriptions. The data was only available directly to regulators working for the Chief Health Officer, with a process for providing patient S8 histories to validated medical practitioners on email or telephone request. The NT Coroner recommended in 2017 that the NT Government implement real time prescription monitoring of Schedule 8 drugs.

The aim of a Real Time Prescription Monitoring (RTPM) system is to reduce the risks of dose escalation, dependence and overdose of select medicines by increasing the sharing of information between prescribers, pharmacists and regulators. RTPMs support clinical decision-making and encourage conversations between health professionals and their patients to identify and reduce the risk of medication related harm.

In July 2020, an agreement was signed between NT Health, the Commonwealth Department of Health and software provider FredIT for the NT to link to the Commonwealth’s federated RTPM and to develop an RTPM system for the NT.

The system is known as NTScript. The date for health practitioner access is not yet decided.

What information is collected?

Prescription details collected by NTScript include:

  • name and address of the patient
  • name and address of prescriber
  • details of the practice where the prescriber is located
  • date prescription is issued by the prescriber
  • medicine details (name, brand, strength, quantity, instructions)
  • details of pharmacy which dispenses the medicine
  • date the medicine is dispensed

Which medicines are monitored?

“Monitored Substances” are those medicines that greatly increase risk to the patient due to likelihood of dose escalation, dependence, overdose, misuse and diversion.

Initially NTScript RTPM will only monitor S8 substances (Controlled Drugs).  These are the same medicines which have been monitored since 1983. However data availability will be far more up to date (real time) and prescribers and pharmacists will have direct access for patients they are treating.

S8 medicines include strong pain relievers such as morphine (e.g. MS ContinR, KapanolR) and oxycodone (e.g. OxyContinR, TarginR), stimulants used to treat ADHD, narcolepsy and autosomal hypersomnolence (e.g. RitalinR, VyvanseR), and opioid substitution medicines methadone, buprenorphine and buprenorphine/naloxone.

At a later stage, monitoring will be extended to include specific S4 medicines (prescription only) as is the case in other states and territories.  The date for inclusion of these S4 medicines is yet to be confirmed. The additional monitored medicines will include:

  • All benzodiazepines not in S8 –  e.g. diazepam (ValiumR, AntenexR)
  • “Z-drugs” – zolpidem (e.g. StilnoxR) and zopiclone (e.g. ImovaneR)
  • quetiapine (e.g. SeroquelR)
  • gabapentin (e.g. NeurontinR)
  • Pregabalin (e..g LyricaR)
  • codeine combination products e.g. Panadeine ForteR
  • tramadol

Supporting safe medicine use

NTScript does not determine if a medicine can or cannot be prescribed or supplied. If someone is receiving monitored medicines at high dose, high risk combinations or receiving monitored medicines from multiple providers they will be at a high risk of harm. Data in NTScript will be used to determine risk, coordinate care and support the safe and effective supply of medicines.

Identifying risks

The information in NTScript will help prescribers and pharmacists work with their patients to identify and manage risks. NTScript will generate Alerts within the software when criteria known to increase risk are present. Clinicians using conformant software will also see pop-up Notifications at the time of prescribing/dispensing to help identify where there is information in NTScript that should be considered.

Can someone opt out?

NTScript continues the mandatory monitoring in place since 1983 in the NT. It is not possible to opt out as the use and supply of these “monitored of substances” is a major public health and safety concern, to individual patients and to the general community.

How is privacy protected?

All data in NTScript is encrypted and stored in accordance with Commonwealth Department of Defence IT Standards. Access to NTScript is limited to prescribers, pharmacists and regulators. Users log in with multifactorial authentication which greatly reduces the risk of unauthorised access. All access to NTScript by any user is logged and privacy is protected under the NT Information Act 2002 and Commonwealth Privacy Act 1988.

How is patient consent managed?

The final decision to have a medicine prescribed or supplied is up to the patient in conjunction with their treating health professional.  Health professionals should inform their patient when a medicine will be included in NTScript so that patients can choose not to receive the monitored medicine and alternative treatment or referral should then be provided instead.

Who can access the information?

  • By law NT Script data can be accessed by certain classes of health practitioner registered with a national board.  The health practitioners are prescribers (doctors, dentists, nurse practitioners, endorsed midwives and podiatrists) and pharmacists. These health practitioners first need to register for NTScript.
  • An authorised user is allowed to access NTScript only to aid clinical decision making for providing direct care to a particular person.
  • NT Department of Health staff who are responsible for the regulation of medicines on behalf of the Chief Health Officer will also have access as part of their duties.
  • Patients can view information held against their details when they are discussing treatment options with their treating health practitioner, provided the health practitioner is registered for NTScript.
  • Patients can also submit a Freedom of Information (FOI) request to the NT Department of Health.

Contact details

Medicines and Poisons
NT Department of Health
Phone: (08) 8922 7341


This page has information for pharmacists about prescription requirements, Schedule 8 (S8) medicines and the pharmacist immunisations.

Pharmacists must familiarise themselves with the Medicines, Poisons and Therapeutic Goods Act and Regulations and the Code of Practice S8 Substances.

To get the S8 Code of Conduct see medical practitioners.

COVID-19 advice

Employer pharmacists are legally obligated to minimise risks to employees in the course of business operations.

During this unprecedented time of COVID-19 disease, employers and managers must ensure the health and safety of all employees and customers.

Read the advice for community pharmacies infection control guide for more information.

S8 website

The secure S8 website has been decommissioned from September 2020.

Pharmacy S8 reports are now to be emailed every week to

Read the Schedule 8 reporting fact sheet.

For information on the Schedule 8 contract list please contact Medicines and Poisons during office hours on (08) 89227 341 or by emailing

Unrestricted S8 substances

Prescribers must notify Medicines and Poisons of the supply of unrestricted S8 substances such as morphine and pethidine if supply exceeds eight weeks, or if other circumstances arise that are in the Code of Practice.

Prescribers also need a special authorisation if they want to prescribe for more than an approved number of patients.

Compliance is the responsibility of the prescriber, and pharmacists are not expected to routinely monitor these matters as a part of dispensing.

However pharmacists may contact Medicines and Poisons if they have particular queries or concerns.

Restricted S8 substances

These categories of S8 substances have the following supply restrictions applied to them.


Stimulants include dexamfetamine, lisdexamfetamine and methylphenidate.

General medical practitioners and nurse practitioners can co-prescribe in conjunction with a specialist paediatrician, psychiatrist, neurologist, physician or registrar in training in one of these disciplines.

Prescribers are required to obtain authorisation before prescribing these substances.

Pharmacists are not required to check whether a prescriber has obtained authorisation, however they may contact Medicines and Poisons with queries or concerns.

Opioid substitution

This includes buprenorphine, buprenorphine/naloxone and methadone 5mg/mL liquid.

Medical practitioners and nurse practitioners providing opioid substitution need to be specially trained and accredited by the Chief Health Officer.

Medicines and Poisons can provide information on whether prescribers are accredited.

Prescription requirements

The S8 Code has these requirements for prescriptions of controlled drugs.
  • prescriptions for unrestricted S8 substances such as morphine are valid for six months, with dispensing of one month’s supply at any one time
  • prescriptions for restricted S8 psycho-stimulants (dexamphetamine, lisdexamfetamine and methylphenidate) are valid for six months
  • prescriptions for restricted S8 substances buprenorphine, buprenorphine/naloxone and methadone 5mg/mL are valid for three months. They must be dispensed within three days of the date of issue or the start date (if different)
  • according to the S8 Code the following items must be written on all S8 prescriptions, in addition to usual requirements for prescriptions:
    • the date of birth of the patient
    • the type of preparation i.e. liquid or sublingual tablets
    • doses in words and numbers for buprenorphine, buprenorphine/naloxone and methadone
    • quantities in words and numbers for unrestricted S8 substances and psycho-stimulant medication.
  • a prescription must be written in ink, not in pencil or another easily erasable material
  • if there are any changes to the details, the initials of the person who issued the prescription and the date the change was made must appear beside each change
  • prescribers must sign prescriptions in their handwriting unless they are using an electronic prescribing system
  • prescribers of buprenorphine, buprenorphine/naloxone and methadone 5mg/mL liquid, also need to include the name of the dispensing pharmacy as well as a detailed dosage regimen and any takeaway privileges.


Drug Loss Discrepancy Report Form
Information sheets
Explanation of Key Tasks - Pharmacy Specific
Summary of Requirements for Pharmacists
Prescriptions and Orders General
Supplying Without a Prescription
Continued Dispensing Initiative
Identification of Prescriber
Disposal of S8 Substances
Alcohol substitution products fact sheet for mouthwash and essence flavourings
Methylated spirits fact sheet
Information Sheet for Community Pharmacists

Related information

Read more about scheduled substances in the Clinical Advisory Committee (CLAC).

For information on the following topics go to medicines and poisons safety:

  • therapeutic goods recalls
  • buying medicines online.

Pharmacist vaccinations

For COVID-19 vaccination administration protocols, go to the COVID-19 Vaccine Protocols page.

Pharmacists have been vaccinating in the NT since 2015. On 29 May 2020 the NT Chief Health Officer approved two new protocols for pharmacist vaccinations.

  • The age criteria for influenza vaccine has changed allowing people 10 years and over to be vaccinated by a pharmacist.
  • Pharmacists must complete a further training unit to vaccinate children 10 to 15.

All other approved vaccinations remain unchanged at 16 years and over.

Pharmacists adhering to the protocol may administer:

  • Influenza Vaccine - 10 years and over
  • Measles/Mumps/Rubella (MMR Vaccine) – 16 years and over
  • Diphtheria/Tetanus/Pertussis Vaccine – 16 years and over

Pharmacists vaccinating at pharmacy premises

Please note that premises must comply with Pharmacy Premises Standard PS5.  

PS5 is mandated and pharmacy owners must have the immunisation room inspected prior to commencing a new immunisation service. There is no need to have your immunisation room reinspected if it has been previously approved.

Pharmacists vaccinating outside pharmacy premises

Pharmacists must adhere to the following protocol which is equivalent to those for nurse vaccinators providing immunisation programs:

Further Information

If you are a pharmacy owner, manager of a pharmacy or pharmacist and you are interested in providing an immunisation service please contact:

The Registrar, Pharmacy Premises Committee


Medicines and Poisons

Therapeutic medicines containing cannabinoids (medicinal cannabis)

The Australian Government Department of Health regulates therapeutic medicines containing cannabinoids through the Therapeutic Goods Administration and for importation or production, the Office of Drug Control.

Access is restricted to appropriate patients with certain medical conditions where there is evidence to support its therapeutic use.

For further information read the:

Patients living in the Northern Territory

A patient living in the Northern Territory must access medicines containing cannabinoids through an Australian doctor who is authorised under the Special Access or Authorised Prescriber Scheme administered by the Therapeutic Goods Administration.

To be dispensed in the NT, S8 prescriptions must be written by a NT based prescriber (based on practice address on the prescription).

For further information read the: